180 Wealth Advisors LLC Boosts Holdings in Axon Enterprise, Inc $AXON

180 Wealth Advisors LLC lifted its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 155.9% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,181 shares of the biotechnology company’s stock after purchasing an additional 6,203 shares during the period. 180 Wealth Advisors LLC’s holdings in Axon Enterprise were worth $4,324,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Evergreen Capital Management LLC boosted its position in Axon Enterprise by 3.8% in the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after buying an additional 15 shares during the period. CWA Asset Management Group LLC boosted its holdings in Axon Enterprise by 5.2% in the fourth quarter. CWA Asset Management Group LLC now owns 387 shares of the biotechnology company’s stock valued at $220,000 after purchasing an additional 19 shares during the period. Synergy Financial Group LTD grew its stake in Axon Enterprise by 1.4% during the 3rd quarter. Synergy Financial Group LTD now owns 1,388 shares of the biotechnology company’s stock worth $996,000 after purchasing an additional 19 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in Axon Enterprise by 1.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,631 shares of the biotechnology company’s stock worth $1,350,000 after purchasing an additional 19 shares in the last quarter. Finally, Strategic Advocates LLC increased its holdings in Axon Enterprise by 1.2% during the 3rd quarter. Strategic Advocates LLC now owns 1,856 shares of the biotechnology company’s stock worth $1,332,000 after purchasing an additional 22 shares during the period. 79.08% of the stock is owned by hedge funds and other institutional investors.

Axon Enterprise Stock Performance

NASDAQ AXON traded down $16.20 during trading hours on Friday, hitting $565.80. The company had a trading volume of 762,731 shares, compared to its average volume of 1,119,821. The business has a 50 day moving average of $457.90 and a 200-day moving average of $483.77. The company has a market cap of $45.60 billion, a PE ratio of 227.23, a price-to-earnings-growth ratio of 11.54 and a beta of 1.38. Axon Enterprise, Inc has a 1-year low of $339.01 and a 1-year high of $885.91. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The business had revenue of $807.35 million for the quarter, compared to analysts’ expectations of $778.90 million. During the same quarter in the previous year, the firm earned $1.47 earnings per share. The business’s revenue was up 33.7% compared to the same quarter last year. As a group, equities research analysts expect that Axon Enterprise, Inc will post 1.63 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. TD Cowen reduced their price target on Axon Enterprise from $950.00 to $825.00 and set a “buy” rating on the stock in a research report on Wednesday, April 8th. Piper Sandler reissued an “overweight” rating and set a $674.00 price objective on shares of Axon Enterprise in a research report on Monday, June 15th. The Goldman Sachs Group set a $535.00 target price on shares of Axon Enterprise in a report on Thursday, May 7th. Weiss Ratings raised shares of Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, May 8th. Finally, UBS Group lowered their price target on shares of Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating for the company in a report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $722.12.

Insider Activity

In other news, CRO Cameron Brooks sold 1,242 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $500.00, for a total value of $621,000.00. Following the completion of the sale, the executive directly owned 49,710 shares of the company’s stock, valued at approximately $24,855,000. This represents a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Isaiah Fields sold 2,000 shares of Axon Enterprise stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $400.00, for a total transaction of $800,000.00. Following the completion of the transaction, the insider directly owned 52,813 shares in the company, valued at $21,125,200. The trade was a 3.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 58,989 shares of company stock worth $30,527,983 over the last ninety days. 4.20% of the stock is owned by corporate insiders.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.